20-25% of renal tumor diagnoses given today are wrong and result in unnecessary surgeries, kidney removals, and in some cases death.

Today renal cancer is diagnosed through CT- or ultrasound-assisted biopsies, which can be a painful and uncomfortable experience for the patient. The method also leads to false positives, which indicates that the condition is present when in reality it is not.

RCC-AI is a science-based project developing a technology that combines AI and clinical expertise to avoid inaccurate renal cancer diagnosis.

The false positives can result in:

• Overtreatment of benign tumors leading to lifelong dialysis, with 3–5-year mortality
• Increased burden on the healthcare system

In Q2 of 2023, RCC-AI received a grant from the Innovation Fund Denmark through their Innoexplorer program to further mature the technology and implement it at the hospitals.

RCC-AI combines expertise from Sjællands Universitetshospital, DTU Chemical and Biochemical Engineering, and Roskilde University, with a strong team consisting of Dr. Nessn Azawi (pictured above), Christian Beenfeldt, Mikkel Pedersen, Abhishek Sivaram, Henrik Bulskov, Henning Christensen, and Associate Professor at DTU, Seyed Mansouri Solheil.